Entries by admin

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director

/in /by

Appointments bring additional respiratory and late clinical-stage drug development experience as Company commences Phase 2a clinical trial of its lead asset Brighton, UK, 17 June 2024:Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced the appointment […]

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

/in /by

Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled to commence Phase 2 clinical study in people with cystic fibrosis in summer 2024 Brighton, UK, 12 June 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical […]

Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical Officer

/in /by

Dr Prasad will lead Enterprise’s development strategy to support the continued advancement of the Company’s respiratory programmes through the clinic Brighton, UK, 8 February 2022: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has […]

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

/in /by

ETD001 is a novel inhaled, long-acting ENaC inhibitor Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 14 June 2021: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has successfully dosed […]

Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche

/in /by

Enterprise’s novel TMEM16A potentiator portfolio includes ETD002, a first in class compound which is currently in Phase 1 TMEM16A potentiation is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit in other respiratory diseases Enterprise’s shareholders received an upfront payment of £75 million Brighton, UK, 07 […]

Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002

/in /by

ETD002 is a novel TMEM16A chloride channel potentiator Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 17 August 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has successfully dosed […]

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

/in /by

Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic Brighton, UK, 10 February 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed […]

Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients

/in /by

“TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance Co-authored by researchers from University of Sussex, University of North Carolina and University of Miami Brighton, UK, 08 January 2020: […]

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019

/in /by

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019 Henry Danahay1,2, Alexis Flen, Camille Ehre3, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University of North Carolina, Chapel Hill, USA. A role for the calcium activated chloride channel, […]